Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) Director Ra Capital Management, L.P. acquired 15,414 shares of the stock in a transaction dated Monday, June 15th. The stock was purchased at an average cost of $8.99 per share, with a total value of $138,571.86. Following the purchase, the director directly owned 16,638,150 shares of the company's stock, valued at $149,576,968.50. This trade represents a 0.09% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.89 per share, with a total value of $1,110,298.77.
- On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.
- On Thursday, June 11th, Ra Capital Management, L.P. acquired 548,580 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $7.91 per share, with a total value of $4,339,267.80.
- On Wednesday, June 10th, Ra Capital Management, L.P. acquired 103 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $7.00 per share, with a total value of $721.00.
- On Tuesday, June 9th, Ra Capital Management, L.P. acquired 479,039 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $6.91 per share, with a total value of $3,310,159.49.
- On Monday, May 11th, Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $11.52 per share, with a total value of $74,999,992.32.
Artiva Biotherapeutics Price Performance
Artiva Biotherapeutics stock opened at $8.91 on Wednesday. The business has a 50 day moving average of $9.02 and a 200-day moving average of $6.23. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53. The company has a market capitalization of $220.26 million, a P/E ratio of -2.52 and a beta of 2.38.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Equities analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.
Analyst Ratings Changes
Several research analysts have recently issued reports on ARTV shares. Wedbush upped their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an "outperform" rating in a research note on Monday, May 11th. Wall Street Zen cut Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a report on Sunday, May 17th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Needham & Company LLC reiterated a "buy" rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Finally, HC Wainwright upped their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a "buy" rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Artiva Biotherapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $39.00.
Read Our Latest Stock Report on Artiva Biotherapeutics
Institutional Trading of Artiva Biotherapeutics
A number of institutional investors have recently bought and sold shares of ARTV. Prelude Capital Management LLC bought a new stake in Artiva Biotherapeutics during the third quarter valued at $41,000. Bank of America Corp DE boosted its position in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock valued at $46,000 after acquiring an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in Artiva Biotherapeutics during the second quarter valued at $53,000. Qube Research & Technologies Ltd bought a new stake in Artiva Biotherapeutics during the second quarter valued at $58,000. Finally, Jane Street Group LLC bought a new stake in Artiva Biotherapeutics during the second quarter valued at $67,000.
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
